The drug will be manufactured at Lupin's facility in Nagpur, India, and the company has announced plans for a near-term launch in the U.S. market.

According to Cipla, the regulatory clearance serves as an important landmark in the Company's journey, allowing it to expand the depth of its oncology portfolio and its foothold in the US market ...

Anciens Huang / Getty Images The balance sheet and the profit and loss (P&L) statements are regularly issued by companies. Such statements provide an ongoing record of a company's financial ...